Tag Archives: updates
Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):
DARPA SubT Tunnel Circuit – August 15-22, 2019 – Pittsburgh, Pa., USA
CLAWAR 2019 – August 26-28, 2019 – Kuala Lumpur, Malaysia
IEEE Africon 2019 – September 25-27, 2019 – Accra, Ghana
ISRR 2019 – October 6-10, 2019 – Hanoi, Vietnam
Ro-Man 2019 – October 14-18, 2019 – New Delhi, India
Humanoids 2019 – October 15-17, 2019 – Toronto, Canada
ARSO 2019 – October 31-1, 2019 – Beijing, China
ROSCon 2019 – October 31-1, 2019 – Macau
IROS 2019 – November 4-8, 2019 – Macau
Let us know if you have suggestions for next week, and enjoy today’s videos.
Lakshmi Nair from Georgia Tech describes some fascinating research towards robots that can create their own tools, as presented at ICRA this year:
Using a novel capability to reason about shape, function, and attachment of unrelated parts, researchers have for the first time successfully trained an intelligent agent to create basic tools by combining objects.
The breakthrough comes from Georgia Tech’s Robot Autonomy and Interactive Learning (RAIL) research lab and is a significant step toward enabling intelligent agents to devise more advanced tools that could prove useful in hazardous – and potentially life-threatening – environments.
[ Lakshmi Nair ]
Victor Barasuol, from the Dynamic Legged Systems Lab at IIT, wrote in to share some new research on their HyQ quadruped that enables sensorless shin collision detection. This helps the robot navigate unstructured environments, and also mitigates all those painful shin strikes, because ouch.
This will be presented later this month at the International Conference on Climbing and Walking Robots (CLAWAR) in Kuala Lumpur, Malaysia.
[ IIT ]
You used to have a tail, you know—as an embryo, about a month in to your development. All mammals used to have tails, and now we just have useless tailbones, which don’t help us with balancing even a little bit. BRING BACK THE TAIL!
The tail, created by Junichi Nabeshima, Kouta Minamizawa, and MHD Yamen Saraiji from Keio University’s Graduate School of Media Design, was presented at SIGGRAPH 2019 Emerging Technologies.
[ Paper ] via [ Gizmodo ]
The noises in this video are fantastic.
[ ESA ]
Apparently the industrial revolution wasn’t a thorough enough beatdown of human knitting, because the robots are at it again.
[ MIT CSAIL ]
Skydio’s drones just keep getting more and more impressive. Now if only they’d make one that I can afford…
[ Skydio ]
The only thing more fun than watching robots is watching people react to robots.
[ SEER ]
There aren’t any robots in this video, but it’s robotics-related research, and very soothing to watch.
[ Stanford ]
In case it wasn’t clear, which it wasn’t, this is a Roboy project. And if you didn’t understand that first video, you definitely won’t understand this second one:
Whatever that t-shirt is at the end (Roboy in sunglasses puking rainbows…?) I need one.
[ Roboy ]
By adding electronics and computation technology to a simple cane that has been around since ancient times, a team of researchers at Columbia Engineering have transformed it into a 21st century robotic device that can provide light-touch assistance in walking to the aged and others with impaired mobility.
The light-touch robotic cane, called CANINE, acts as a cane-like mobile assistant. The device improves the individual’s proprioception, or self-awareness in space, during walking, which in turn improves stability and balance.
[ ROAR Lab ]
During the second field experiment for DARPA’s OFFensive Swarm-Enabled Tactics (OFFSET) program, which took place at Fort Benning, Georgia, teams of autonomous air and ground robots tested tactics on a mission to isolate an urban objective. Similar to the way a firefighting crew establishes a boundary around a burning building, they first identified locations of interest and then created a perimeter around the focal point.
[ DARPA ]
I think there’s a bit of new footage here of Ghost Robotics’ Vision 60 quadruped walking around without sensors on unstructured terrain.
[ Ghost Robotics ]
If you’re as tired of passenger drone hype as I am, there’s absolutely no need to watch this video of NEC’s latest hover test.
[ AP ]
As researchers teach robots to perform more and more complex tasks, the need for realistic simulation environments is growing. Existing techniques for closing the reality gap by approximating real-world physics often require extensive real world data and/or thousands of simulation samples. This paper presents TuneNet, a new machine learning-based method to directly tune the parameters of one model to match another using an iterative residual tuning technique. TuneNet estimates the parameter difference between two models using a single observation from the target and minimal simulation, allowing rapid, accurate and sample-efficient parameter estimation.
The system can be trained via supervised learning over an auto-generated simulated dataset. We show that TuneNet can perform system identification, even when the true parameter values lie well outside the distribution seen during training, and demonstrate that simulators tuned with TuneNet outperform existing techniques for predicting rigid body motion. Finally, we show that our method can estimate real-world parameter values, allowing a robot to perform sim-to-real task transfer on a dynamic manipulation task unseen during training. We are also making a baseline implementation of our code available online.
[ Paper ]
Here’s an update on what GITAI has been up to with their telepresence astronaut-replacement robot.
[ GITAI ]
Curiosity captured this 360-degree panorama of a location on Mars called “Teal Ridge” on June 18, 2019. This location is part of a larger region the rover has been exploring called the “clay-bearing unit” on the side of Mount Sharp, which is inside Gale Crater. The scene is presented with a color adjustment that approximates white balancing to resemble how the rocks and sand would appear under daytime lighting conditions on Earth.
[ MSL ]
Some updates (in English) on ROS from ROSCon France. The first is a keynote from Brian Gerkey:
And this second video is from Omri Ben-Bassat, about how to keep your Anki Vector alive using ROS:
All of the ROSCon FR talks are available on Vimeo.
[ ROSCon FR ] Continue reading
The Tunnel Circuit of the DARPA Subterranean Challenge starts later this week at the NIOSH research mine just outside of Pittsburgh, Pennsylvania. From 15-22 August, 11 teams will send robots into a mine that they've never seen before, with the goal of making maps and locating items. All DARPA SubT events involve tunnels of one sort or another, but in this case, the “Tunnel Circuit” refers to mines as opposed to urban underground areas or natural caves. This month’s challenge is the first of three discrete events leading up to a huge final event in August of 2021.
While the Tunnel Circuit competition will be closed to the public, and media are only allowed access for a single day (which we'll be at, of course), DARPA has provided a substantial amount of information about what teams will be able to expect. We also have details from the SubT Integration Exercise, called STIX, which was a completely closed event that took place back in April. STIX was aimed at giving some teams (and DARPA) a chance to practice in a real tunnel environment.
For more general background on SubT, here are some articles to get you all caught up:
SubT: The Next DARPA Challenge for Robotics
Q&A with DARPA Program Manager Tim Chung
Meet The First Nine Teams
It makes sense to take a closer look at what happened at April's STIX exercise, because it is (probably) very similar to what teams will experience in the upcoming Tunnel Circuit. STIX took place at Edgar Experimental Mine in Colorado, and while no two mines are the same (and many are very, very different), there are enough similarities for STIX to have been a valuable experience for teams. Here's an overview video of the exercise from DARPA:
DARPA has also put together a much more detailed walkthrough of the STIX mine exercise, which gives you a sense of just how vast, complicated, and (frankly) challenging for robots the mine environment is:
So, that's the kind of thing that teams had to deal with back in April. Since the event was an exercise, rather than a competition, DARPA didn't really keep score, and wouldn't comment on the performance of individual teams. We've been trolling YouTube for STIX footage, though, to get a sense of how things went, and we found a few interesting videos.
Here's a nice overview from Team CERBERUS, which used drones plus an ANYmal quadruped:
Team CTU-CRAS also used drones, along with a tracked robot:
Team Robotika was brave enough to post video of a “fatal failure” experienced by its wheeled robot; the poor little bot gets rescued at about 7:00 in case you get worried:
So that was STIX. But what about the Tunnel Circuit competition this week? Here's a course preview video from DARPA:
It sort of looks like the NIOSH mine might be a bit less dusty than the Edgar mine was, but it could also be wetter and muddier. It’s hard to tell, because we’re just getting a few snapshots of what’s probably an enormous area with kilometers of tunnels that the robots will have to explore. But DARPA has promised “constrained passages, sharp turns, large drops/climbs, inclines, steps, ladders, and mud, sand, and/or water.” Combine that with the serious challenge to communications imposed by the mine itself, and robots will have to be both physically capable, and almost entirely autonomous. Which is, of course, exactly what DARPA is looking to test with this challenge.
Lastly, we had a chance to catch up with Tim Chung, Program Manager for the Subterranean Challenge at DARPA, and ask him a few brief questions about STIX and what we have to look forward to this week.
IEEE Spectrum: How did STIX go?
Tim Chung: It was a lot of fun! I think it gave a lot of the teams a great opportunity to really get a taste of what these types of real world environments look like, and also what DARPA has in store for them in the SubT Challenge. STIX I saw as an experiment—a learning experience for all the teams involved (as well as the DARPA team) so that we can continue our calibration.
What do you think teams took away from STIX, and what do you think DARPA took away from STIX?
I think the thing that teams took away was that, when DARPA hosts a challenge, we have very audacious visions for what the art of the possible is. And that's what we want—in my mind, the purpose of a DARPA Grand Challenge is to provide that inspiration of, ‘Holy cow, someone thinks we can do this!’ So I do think the teams walked away with a better understanding of what DARPA's vision is for the capabilities we're seeking in the SubT Challenge, and hopefully walked away with a better understanding of the technical, physical, even maybe mental challenges of doing this in the wild— which will all roll back into how they think about the problem, and how they develop their systems.
This was a collaborative exercise, so the DARPA field team was out there interacting with the other engineers, figuring out what their strengths and weaknesses and needs might be, and even understanding how to handle the robots themselves. That will help [strengthen] connections between these university teams and DARPA going forward. Across the board, I think that collaborative spirit is something we really wish to encourage, and something that the DARPA folks were able to take away.
What do we have to look forward to during the Tunnel Circuit?
The vision here is that the Tunnel Circuit is representative of one of the three subterranean subdomains, along with urban and cave. Characteristics of all of these three subdomains will be mashed together in an epic final course, so that teams will have to face hints of tunnel once again in that final event.
Without giving too much away, the NIOSH mine will be similar to the Edgar mine in that it's a human-made environment that supports mining operations and research. But of course, every site is different, and these differences, I think, will provide good opportunities for the teams to shine.
Again, we'll be visiting the NIOSH mine in Pennsylvania during the Tunnel Circuit and will post as much as we can from there. But if you’re an actual participant in the Subterranean Challenge, please tweet me @BotJunkie so that I can follow and help share live updates.
[ DARPA Subterranean Challenge ] Continue reading
The causes of aging are extremely complex and unclear. With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to find practical ways to extend our healthspan.
Here, in Part 2 of a series of blogs on longevity and vitality, I explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.
In this blog I’ll cover two classes of emerging technologies:
Genome Sequencing and Editing;
Senolytics, Nutraceuticals & Pharmaceuticals.
Let’s dive in.
Genome Sequencing & Editing
Your genome is the software that runs your body.
A sequence of 3.2 billion letters makes you “you.” These base pairs of A’s, T’s, C’s, and G’s determine your hair color, your height, your personality, your propensity to disease, your lifespan, and so on.
Until recently, it’s been very difficult to rapidly and cheaply “read” these letters—and even more difficult to understand what they mean.
Since 2001, the cost to sequence a whole human genome has plummeted exponentially, outpacing Moore’s Law threefold. From an initial cost of $3.7 billion, it dropped to $10 million in 2006, and to $5,000 in 2012.
Today, the cost of genome sequencing has dropped below $500, and according to Illumina, the world’s leading sequencing company, the process will soon cost about $100 and take about an hour to complete.
This represents one of the most powerful and transformative technology revolutions in healthcare.
When we understand your genome, we’ll be able to understand how to optimize “you.”
We’ll know the perfect foods, the perfect drugs, the perfect exercise regimen, and the perfect supplements, just for you.
We’ll understand what microbiome types, or gut flora, are ideal for you (more on this in a later blog).
We’ll accurately predict how specific sedatives and medicines will impact you.
We’ll learn which diseases and illnesses you’re most likely to develop and, more importantly, how to best prevent them from developing in the first place (rather than trying to cure them after the fact).
CRISPR Gene Editing
In addition to reading the human genome, scientists can now edit a genome using a naturally-occurring biological system discovered in 1987 called CRISPR/Cas9.
Short for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9, the editing system was adapted from a naturally-occurring defense system found in bacteria.
Here’s how it works:
The bacteria capture snippets of DNA from invading viruses (or bacteriophage) and use them to create DNA segments known as CRISPR arrays.
The CRISPR arrays allow the bacteria to “remember” the viruses (or closely related ones), and defend against future invasions.
If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses’ DNA. The bacteria then use Cas9 to cut the DNA apart, which disables the virus.
Most importantly, CRISPR is cheap, quick, easy to use, and more accurate than all previous gene editing methods. As a result, CRISPR/Cas9 has swept through labs around the world as the way to edit a genome.
A short search in the literature will show an exponential rise in the number of CRISPR-related publications and patents.
2018: Filled With CRISPR Breakthroughs
Early results are impressive. Researchers from the University of Chicago recently used CRISPR to genetically engineer cocaine resistance into mice.
Researchers at the University of Texas Southwestern Medical Center used CRISPR to reverse the gene defect causing Duchenne muscular dystrophy (DMD) in dogs (DMD is the most common fatal genetic disease in children).
With great power comes great responsibility, and moral and ethical dilemmas.
In 2015, Chinese scientists sparked global controversy when they first edited human embryo cells in the lab with the goal of modifying genes that would make the child resistant to smallpox, HIV, and cholera.
Three years later, in November 2018, researcher He Jiankui informed the world that the first set of CRISPR-engineered female twins had been delivered.
To accomplish his goal, Jiankui deleted a region of a receptor on the surface of white blood cells known as CCR5, introducing a rare, natural genetic variation that makes it more difficult for HIV to infect its favorite target, white blood cells.
Setting aside the significant ethical conversations, CRISPR will soon provide us the tools to eliminate diseases, create hardier offspring, produce new environmentally resistant crops, and even wipe out pathogens.
Senolytics, Nutraceuticals & Pharmaceuticals
Over the arc of your life, the cells in your body divide until they reach what is known as the Hayflick limit, or the number of times a normal human cell population will divide before cell division stops, which is typically about 50 divisions.
What normally follows next is programmed cell death or destruction by the immune system. A very small fraction of cells, however, become senescent cells and evade this fate to linger indefinitely.
These lingering cells secrete a potent mix of molecules that triggers chronic inflammation, damages the surrounding tissue structures, and changes the behavior of nearby cells for the worse.
Senescent cells appear to be one of the root causes of aging, causing everything from fibrosis and blood vessel calcification, to localized inflammatory conditions such as osteoarthritis, to diminished lung function.
Fortunately, both the scientific and entrepreneurial communities have begun to work on senolytic therapies, moving the technology for selectively destroying senescent cells out of the laboratory and into a half-dozen startup companies.
Prominent companies in the field include the following:
Unity Biotechnology is developing senolytic medicines to selectively eliminate senescent cells with an initial focus on delivering localized therapy in osteoarthritis, ophthalmology and pulmonary disease.
Oisin Biotechnologiesis pioneering a programmable gene therapy that can destroy cells based on their internal biochemistry.
SIWA Therapeuticsis working on an immunotherapy approach to the problem of senescent cells.
In recent years, researchers have identified or designed a handful of senolytic compounds that can curb aging by regulating senescent cells. Two of these drugs that have gained mainstay research traction are rapamycin and metformin.
Originally extracted from bacteria found on Easter Island, Rapamycin acts on the m-TOR (mechanistic target of rapamycin) pathway to selectively block a key protein that facilitates cell division.
Currently, rapamycin derivatives are widely used as immunosuppression in organ and bone marrow transplants. Research now suggests that use results in prolonged lifespan and enhanced cognitive and immune function.
PureTech Health subsidiary resTORbio (which started 2018 by going public) is working on a rapamycin-based drug intended to enhance immunity and reduce infection. Their clinical-stage RTB101 drug works by inhibiting part of the mTOR pathway.
Results of the drug’s recent clinical trial include:
Decreased incidence of infection
Improved influenza vaccination response
A 30.6 percent decrease in respiratory tract infections
Impressive, to say the least.
Metformin is a widely-used generic drug for mitigating liver sugar production in Type 2 diabetes patients.
Researchers have found that Metformin also reduces oxidative stress and inflammation, which otherwise increase as we age.
There is strong evidence that Metformin can augment cellular regeneration and dramatically mitigate cellular senescence by reducing both oxidative stress and inflammation.
Over 100 studies registered on ClinicalTrials.gov are currently following up on strong evidence of Metformin’s protective effect against cancer.
Nutraceuticals and NAD+
Beyond cellular senescence, certain critical nutrients and proteins tend to decline as a function of age. Nutraceuticals combat aging by supplementing and replenishing these declining nutrient levels.
NAD+ exists in every cell, participating in every process from DNA repair to creating the energy vital for cellular processes. It’s been shown that NAD+ levels decline as we age.
The Elysium Health Basis supplement aims to elevate NAD+ levels in the body to extend one’s lifespan. Elysium’s clinical study reports that Basis increases NAD+ levels consistently by a sustained 40 percent.
These are just a taste of the tremendous momentum that longevity and aging technology has right now. As artificial intelligence and quantum computing transform how we decode our DNA and how we discover drugs, genetics and pharmaceuticals will become truly personalized.
The next blog in this series will demonstrate how artificial intelligence is converging with genetics and pharmaceuticals to transform how we approach longevity, aging, and vitality.
We are edging closer to a dramatically extended healthspan—where 100 is the new 60. What will you create, where will you explore, and how will you spend your time if you are able to add an additional 40 healthy years to your life?
Abundance Digital is my online educational portal and community of abundance-minded entrepreneurs. You’ll find weekly video updates from Peter, a curated newsfeed of exponential news, and a place to share your bold ideas. Click here to learn more and sign up.
Image Credit: ktsdesign / Shutterstock.com Continue reading